Becton, Dickinson and Company (NYSE:BDX) Posts Earnings Results, Beats Expectations By $0.04 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04, Zacks reports. The business had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the business posted $3.81 EPS. Becton, Dickinson and Company updated its FY 2026 guidance to 14.750-15.050 EPS.

Becton, Dickinson and Company Stock Up 0.3%

Shares of NYSE:BDX traded up $0.49 during trading on Friday, hitting $177.88. 3,068,583 shares of the company were exchanged, compared to its average volume of 2,454,233. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The stock has a market cap of $50.99 billion, a price-to-earnings ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a fifty day moving average price of $186.77 and a two-hundred day moving average price of $182.42.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 71.36%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BDX shares. Jefferies Financial Group dropped their price target on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Argus lifted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $203.27.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,249 shares of company stock valued at $231,358 over the last three months. 0.36% of the stock is owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently added to or reduced their stakes in the company. Caxton Associates LLP acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at $212,000. Oxford Asset Management LLP bought a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $271,000. State of Wyoming acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at about $352,000. Teza Capital Management LLC bought a new position in Becton, Dickinson and Company during the second quarter worth about $379,000. Finally, Voleon Capital Management LP acquired a new stake in Becton, Dickinson and Company in the 2nd quarter worth about $381,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.